SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

13 $85.9 $89.3 $72.6 $62.7 $8.2 $6.1 $0.8 $0.1 $0.0 $20.0 $40.0 $60.0 $80.0 $100.0 $120.0 2015 2016 2017 2018E Adjusted SG&A R&D 2015 – 2018E Adjusted Operating Expenses ($M) (1) ▪ Management has overseen a significant rationalization of Pernix’s cost structure in recent years ▪ 2018 adjusted operating expenses are projected to be 33% (or $31 million (1) ) lower than in 2015, driven by: • Two sales force reorganizations • Elimination of low ROI R&D projects • Rationalization of home office staff • Tight management of third party spend ▪ As a result, Adjusted EBITDA nearly doubled from 2016 to 2017 despite a 6.4% drop in Adjusted Net Sales 1) Represents fully burdened Pernix operating expenses, excluding any shared service reimbursement from Nalpropion . SG&A is non - GAAP, pro - forma for certain adjustments. $94.1 $95.4 $73.4 $62.7 Proven Leadership Team With Success In Driving Cost Savings